BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis 2020;14:1202-13. [PMID: 32161949 DOI: 10.1093/ecco-jcc/jjaa049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lu Q, Yang M, Liang Y, Xu J, Xu H, Nie Y, Wang L, Yao J, Li D. Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. JIR 2022;Volume 15:1825-44. [DOI: 10.2147/jir.s353038] [Reference Citation Analysis]
3 Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Reference Citation Analysis]
4 Grossberg LB, Papamichael K, Cheifetz AS. Review: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 35166398 DOI: 10.1111/apt.16785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol 2020;55:141-50. [PMID: 33254032 DOI: 10.1016/j.coph.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zhang Z, Ghosh A, Connolly PJ, King P, Wilde T, Wang J, Dong Y, Li X, Liao D, Chen H, Tian G, Suarez J, Bonnette WG, Pande V, Diloreto KA, Shi Y, Patel S, Pietrak B, Szewczuk L, Sensenhauser C, Dallas S, Edwards JP, Bachman KE, Evans DC. Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer. J Med Chem 2021;64:11570-96. [PMID: 34279934 DOI: 10.1021/acs.jmedchem.1c00890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cohen NA, Rubin DT. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol 2021;37:357-63. [PMID: 34059604 DOI: 10.1097/MOG.0000000000000740] [Reference Citation Analysis]
8 Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford) 2021;60:ii45-51. [PMID: 33950226 DOI: 10.1093/rheumatology/keaa896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, Brasier AR, Pinchuk IV, Tian B, Zhou J. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S38-62. [PMID: 34791293 DOI: 10.1093/ibd/izab190] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hartwig O, Loretz B, Nougarede A, Jary D, Sulpice E, Gidrol X, Navarro F, Lehr CM. Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1. J Control Release 2022:S0168-3659(22)00163-8. [PMID: 35339579 DOI: 10.1016/j.jconrel.2022.03.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Alexander M, Luo Y, Raimondi G, O'Shea JJ, Gadina M. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies. Pharmaceuticals (Basel) 2021;15:48. [PMID: 35056105 DOI: 10.3390/ph15010048] [Reference Citation Analysis]
12 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Reference Citation Analysis]
13 Ma C, Panaccione R. Harnessing localised delivery of gut-selective therapy for ulcerative colitis. Lancet Gastroenterol Hepatol 2020;5:1031-2. [PMID: 33031759 DOI: 10.1016/S2468-1253(20)30292-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Nobel YR, Stier K, Krishnareddy S. STAT signaling in the intestine. Int Rev Cell Mol Biol 2021;361:1-20. [PMID: 34074491 DOI: 10.1016/bs.ircmb.2021.02.001] [Reference Citation Analysis]
16 Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol 2021;147:814-26. [PMID: 33129886 DOI: 10.1016/j.jaci.2020.10.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
17 Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021;6:402. [PMID: 34824210 DOI: 10.1038/s41392-021-00791-1] [Reference Citation Analysis]
18 Luo Y, Alexander M, Gadina M, O'Shea JJ, Meylan F, Schwartz DM. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. J Allergy Clin Immunol 2021;148:911-25. [PMID: 34625141 DOI: 10.1016/j.jaci.2021.08.004] [Reference Citation Analysis]
19 Moon SY, Kim KD, Yoo J, Lee JH, Hwangbo C. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. Molecules 2021;26:2824. [PMID: 34068714 DOI: 10.3390/molecules26092824] [Reference Citation Analysis]
20 Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S. JAK inhibitors in crohn's disease: ready to go? Expert Opin Investig Drugs 2022;31:145-61. [PMID: 35164629 DOI: 10.1080/13543784.2022.2032639] [Reference Citation Analysis]
21 Zheng J, Wu J, Ding X, Shen HC, Zou G. Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. Bioorg Med Chem Lett 2021;38:127862. [PMID: 33609659 DOI: 10.1016/j.bmcl.2021.127862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Zarrin AA, Bao K, Lupardus P, Vucic D. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov 2021;20:39-63. [PMID: 33077936 DOI: 10.1038/s41573-020-0082-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
23 Caballol B, Gudiño V, Panes J, Salas A. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34365869 DOI: 10.1080/13543784.2021.1965122] [Reference Citation Analysis]
24 D'Amico F, Peyrin-Biroulet L, Danese S. JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. J Crohns Colitis 2020;14:1185-7. [PMID: 32579170 DOI: 10.1093/ecco-jcc/jjaa074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol 2021;12:651415. [PMID: 33935763 DOI: 10.3389/fphar.2021.651415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
26 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
27 Spiewak TA, Patel A. User's Guide to JAK Inhibitors in Inflammatory Bowel Disease. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100096] [Reference Citation Analysis]
28 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
29 Modi NB, Cheng X, Mattheakis L, Hwang CC, Nawabi R, Liu D, Gupta S. Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 33942566 DOI: 10.1002/cpdd.946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]